# EDGAR Filing Document

**Accession Number:** 0001773751
**File Stem:** 0001773751-23-000027
**Filing Date:** 2023-2
**Character Count:** 40781
**Document Hash:** 61eb73995d3959a40a7488040e9d60b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001773751-23-000027.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001773751-23-000027

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230227

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hims & Hers Health, Inc.
- **CENTRAL INDEX KEY:** 0001773751
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38986
- **FILM NUMBER:** 23675190

**BUSINESS ADDRESS:**
- **STREET 1:** 2269 CHESTNUT ST
- **STREET 2:** #523
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94123
- **BUSINESS PHONE:** 415-851-0195

**MAIL ADDRESS:**
- **STREET 1:** 2269 CHESTNUT ST
- **STREET 2:** #523
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94123

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oaktree Acquisition Corp.
- **DATE OF NAME CHANGE:** 20190412

?xml version="1.0" ? hims-20230227

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 27, 2023**

**HIMS & HERS HEALTH, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | | **001-38986** | **98-1482650** |
| **(State or other jurisdiction**<br>**of incorporation)** | | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **2269 Chestnut Street, #523** | **2269 Chestnut Street, #523** | **2269 Chestnut Street, #523** | **94123** |
| **San Francisco** | **,** | **California** | **(Zip Code)** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Address of principal executive offices)** | |

---

**Registrant's telephone number, including area code: (415) 851-0195**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

------

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| Class A common stock, $0.0001 par value | HIMS | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.** |

---

On February 27, 2023, Hims & Hers Health, Inc. (the "Company") issued a press release announcing its results of operations for the quarter and year ended December 31, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.

The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | | |
|:---|:---|:---|
| Exhibit No. | <u>Description</u> | <u>Description</u> |
| 99.1 | | <u>[Press Release issued by the Company on February 2](hims-20221231x8xkearningre.htm)[7](hims-20221231x8xkearningre.htm)[, 202](hims-20221231x8xkearningre.htm)[3](hims-20221231x8xkearningre.htm)[announcing results for the quarter and year ended December 31, 20](hims-20221231x8xkearningre.htm)[2](hims-20221231x8xkearningre.htm)[2](hims-20221231x8xkearningre.htm)</u> |
| 104 | | Cover Page Interactive Data file (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **HIMS & HERS HEALTH, INC.** | **HIMS & HERS HEALTH, INC.** |
| DATE: February 27, 2023 | By: | /s/ Oluyemi Okupe |
|  |  | Oluyemi Okupe |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

## Exhibit 99.1

**Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results** 

*Full year 2022 revenue of $526.9 million, up 94% year-over-year*

*Q4 2022 record revenue of $167.2 million, up 97% year-over-year*

*Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million* 

*Eclipses one million subscribers at year end, up 88% year-over-year*

*Provides Q1 and full year 2023 guidance, with full year 2023 revenue in the range of $735 million to $755 million and Adjusted EBITDA in the range of $20 million to $30 million*

*Introduces 2025 targets of at least $1.2 billion in revenue and $100 million in Adjusted EBITDA*

SAN FRANCISCO, February 27, 2023 – Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

"2022 was a year of outstanding execution across the company, as we surpassed one million Subscribers on the platform and made significant strides in delivering on our mission to make the world feel great through the power of better health," said Andrew Dudum, co-founder and CEO. "New technological advancements, acquisition of key talent, ongoing brand strength, and operational excellence fueled strong growth across the business. We entered 2023 with tremendous momentum and are poised to drive top-line growth and profitability as we focus on four strategic pillars: building a trusted brand, deploying leading technology, developing innovative products and services, and ensuring clinical excellence, which will enable us to continue to execute on our mission and extend our reach."

"We are excited by the large market opportunity in front of us. It is clear that our operating model is fueling strong results and momentum. Notably, the transition to positive Adjusted EBITDA in the fourth quarter provides us with additional flexibility to continue building scale," said Yemi Okupe, CFO. "With the strong foundation we have laid and our track record of operational excellence, we are well-positioned to deliver on the 2023 outlook and longer term goals we're introducing today."

------

**Key Business Metrics**

*(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
|  | **2022** | **2021** | **% Change** | **2022** | **2021** | **% Change** |
| Subscribers (end of period) | 1040 | 554 | 88% | 1040 | 554 | 88% |
| Monthly Online Revenue per Average Subscriber | $55 | $50 | 10% | $53 | $51 | 4% |
| Subscriptions (end of period) | 1116 | 609 | 83% | 1116 | 609 | 83% |
| Net Orders | 1855 | 1063 | 75% | 6122 | 3504 | 75% |
| AOV | $87 | $74 | 18% | $82 | $74 | 11% |

---

**Revenue**

*(In Thousands, Unaudited)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
|  | **2022** | **2021** | **% Change** | **2022** | **2021** | **% Change** |
| Online Revenue | $161162 | $78312 | 106% | $502507 | $259170 | 94% |
| Wholesale Revenue | 6041 | 6387 | (5)% | 24409 | 12708 | 92% |
| Total revenue | $167203 | $84699 | 97% | $526916 | $271878 | 94% |

---

Please see the discussion in "Revenue and Key Business Metrics" in Item 7 (Management's Discussion & Analysis of Financial Condition and Results of Operations) of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for a discussion of recent and upcoming changes to our key business metrics.

**Fourth Quarter 2022 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue** was $167.2 million for the fourth quarter of 2022 compared to $84.7 million for the fourth quarter of 2021, an increase of 97% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Gross margin** was 79% for the fourth quarter of 2022 compared to 73% for the fourth quarter of 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net loss** was $(10.9) million in the fourth quarter of 2022 compared to $(31.2) million for the fourth quarter of 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted EBITDA** was $3.9 million for the fourth quarter of 2022 compared to $(7.1) million for the fourth quarter of 2021.

**Full Year 2022 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* **Revenue** was $526.9 million for the year ended December 31, 2022 compared to $271.9 million for the year ended December 31, 2021, an increase of 94% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* **Gross margin** was 78% for the year ended December 31, 2022 compared to 75% for the year ended December 31, 2021.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net loss** was $(65.7) million for the year ended December 31, 2022 compared to $(107.7) million for the year ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* **Adjusted EBITDA** was $(15.8) million for the year ended December 31, 2022 compared to $(30.1) million for the year ended December 31, 2021.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States ("U.S. GAAP"), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading "Non-GAAP Financial Measures".

**2023 Financial Outlook**

Hims & Hers is providing the following 2023 guidance:

**For the first quarter 2023, we expect:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $175 million to $180 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $3 million to $6 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

**For the full year 2023, we expect:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $735 million to $755 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $20 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.

**2025 Financial Targets**

Hims & Hers has demonstrated a consistent track record of execution driven by the strength of its business model and operational excellence, which is fueling strong top line growth and Adjusted EBITDA profitability. Given its large market opportunity and growing customer demand, the Company is providing financial targets for the full year 2025, which include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of at least $1.2 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of at least $100 million.

The guidance and targets provided above constitute forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

------

**Conference Call**

Hims & Hers will host a conference call to review the fourth quarter and full year 2022 results on February 27, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

**About Hims & Hers Health, Inc.**

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit <u>https://investors.forhims.com/</u>.

**Cautionary Note Regarding Forward-Looking Statements**

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believe," "estimate," "anticipate," "expect," "assume," "imply," "intend," "plan," "may," "will," "potential," "project," "predict," "continue," "could," or "should," or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies, the success of our business model, our ability to scale our business, the growth of certain of our categories and the impact of our acquisitions, our ability to expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us

------

may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission").

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

------

**Key Business Metrics**

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting "Subscribers" and "Monthly Online Revenue Per Average Subscriber" as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories the Company serves, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we anticipate no longer reporting "Subscriptions" as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users' engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

**"Online Revenue"** represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

**"Wholesale Revenue"** represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

**"Subscribers"** are customers who have one or more Subscriptions pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence.

**"Monthly Online Revenue per Average Subscriber"** is defined as Online Revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. **"Average Subscribers"** are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

**"Subscriptions"** are defined as the number of customer agreements where the customer has agreed to be automatically billed on a recurring basis at a defined cadence. The billing cadence is typically defined as a number of months (for example, billed every month or every three months). Subscriptions are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscription billing is preferred by many of our customers because most of the products and services we make available are most effective when taken consistently and continuously. Customers can cancel subscriptions in between billing periods to stop receiving additional products and services and can reactivate subscriptions to continue receiving additional products and services. Subscriptions are sometimes also referred to by us as "subscription memberships" or "memberships."

**"Net Orders"** are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our

------

platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

**Average Order Value ("AOV")** is defined as Online Revenue divided by Net Orders (each as defined above).

------

**CONDENSED CONSOLIDATED BALANCE SHEETS**

*(In Thousands, Except Share and Per Share Data, Unaudited)*

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2022** | **2021** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $46772 | $71784 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 132853 | 175490 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 21562 | 13558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 15408 | 9073 |
| Total current assets | 216595 | 269905 |
| Restricted cash | 856 | 856 |
| Goodwill | 110881 | 110881 |
| Intangibles, net | 21841 | 25890 |
| Operating lease right-of-use assets | 4936 | 5111 |
| Other long-term assets | 11232 | 7942 |
| Total assets | $366341 | $420585 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $32363 | $19640 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 12448 | 12194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 1472 | 3188 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Earn-out payable |  | 42834 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 1658 | 1365 |
| Total current liabilities | 47941 | 79221 |
| Operating lease liabilities | 3649 | 4117 |
| Earn-out liabilities | 2975 | 1999 |
| Other long-term liabilities | 35 | 629 |
| Total liabilities | 54600 | 85966 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,051,689 and 196,414,363 shares issued and outstanding as of December 31, 2022 and 2021, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2022 and 2021 | 21 | 20 |
| Additional paid-in capital | 656626 | 613687 |
| Accumulated other comprehensive loss | (277) | (137) |
| Accumulated deficit | (344629) | (278951) |
| Total stockholders' equity | 311741 | 334619 |
| Total liabilities and stockholders' equity | $366341 | $420585 |

---

------

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

*(In Thousands, Except Share and Per Share Data, Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Revenue | $167203 | $84699 | $526916 | $271878 |
| Cost of revenue | 34866 | 22601 | 118194 | 67384 |
| Gross profit | 132337 | 62098 | 408722 | 204494 |
| Gross margin % | 79% | 73% | 78% | 75% |
| Operating expenses:<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing | 85542 | 42707 | 272587 | 135902 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operations and support | 22521 | 13845 | 77403 | 47593 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology and development | 8311 | 5572 | 29237 | 22379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 27568 | 21539 | 98192 | 113662 |
| Total operating expenses | 143942 | 83663 | 477419 | 319536 |
| Loss from operations | (11605) | (21565) | (68697) | (115042) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of liabilities | (942) | (9808) | 70 | 3802 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 1519 | 125 | 2918 | 445 |
| Total other income (expense), net | 577 | (9683) | 2988 | 4247 |
| Loss before income taxes | (11028) | (31248) | (65709) | (110795) |
| Benefit from income taxes | 121 | 87 | 31 | 3136 |
| Net loss | (10907) | (31161) | (65678) | (107659) |
| Other comprehensive income (loss) | 185 | (85) | (140) | (126) |
| Total comprehensive loss | $(10722) | $(31246) | $(65818) | $(107785) |
| Net loss per share attributable to common stockholders: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(0.05) | $(0.15) | $(0.32) | $(0.58) |
| Weighted average shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 206140283 | 201363338 | 204516120 | 186781537 |

---

______________

(1)Includes stock-based compensation expense as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Marketing | $1512 | $4718 | $4648 | $9664 |
| Operations and support | 836 | 302 | 2684 | 2735 |
| Technology and development | 1328 | 989 | 4327 | 4481 |
| General and administrative | 8674 | 5943 | 31158 | 50331 |
| Total stock-based compensation expense | $12350 | $11952 | $42817 | $67211 |

---

------

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

*(In Thousands, Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** |
| **Operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(65678) | $(107659) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 7474 | 4075 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 42817 | 67211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of liabilities | (70) | (3802) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant expense in connection with Merger |  | 154 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs |  | 144 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net amortization on securities | 146 | 2166 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefit for deferred taxes | (594) | (3388) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of long-lived assets | 1127 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash operating lease cost | 1605 | 1510 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash acquisition-related costs | 837 | 1182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash other |  | 540 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (8004) | (9628) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (6335) | 3200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 17 | (58) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 12723 | 9853 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 909 | 197 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (1716) | 1412 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (1605) | (1521) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Earn-out payable | (10184) |  |
| &nbsp;&nbsp;&nbsp;Net cash used in operating activities | (26531) | (34412) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of investments | (187700) | (266633) |
| &nbsp;&nbsp;&nbsp;Maturities of investments | 194259 | 158375 |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of investments | 35846 | 3465 |
| &nbsp;&nbsp;&nbsp;Investment in website and mobile application development and internal-use software | (4533) | (4175) |
| &nbsp;&nbsp;&nbsp;Purchases of property, equipment, and intangible assets | (2714) | (832) |
| &nbsp;&nbsp;&nbsp;Deferred consideration paid for acquisitions | (459) |  |
| &nbsp;&nbsp;&nbsp;Acquisition of businesses, net of cash acquired |  | (46468) |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 34699 | (156268) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Pre-closing stock repurchase |  | (22027) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock upon Merger |  | 197686 |
| &nbsp;&nbsp;&nbsp;Proceeds from PIPE |  | 75000 |
| &nbsp;&nbsp;&nbsp;Payments for transaction costs related to securities issuances |  | (12851) |
| &nbsp;&nbsp;&nbsp;Proceeds from repayment of promissory notes associated with vested and unvested shares |  | 1193 |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of Class A common stock warrants, net of redemption payments |  | 787 |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations | 2246 | 1253 |
| &nbsp;&nbsp;&nbsp;Payments for taxes related to net share settlement of equity awards | (3901) | (5998) |
| &nbsp;&nbsp;&nbsp;Payments for earn-out consideration for acquisitions | (32650) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from employee stock purchase plan | 1178 |  |
| Net cash (used in) provided by financing activities | (33127) | 235043 |
| Foreign currency effect on cash and cash equivalents | (53) | (73) |
| (Decrease) increase in cash, cash equivalents, and restricted cash | (25012) | 44290 |
| Cash, cash equivalents, and restricted cash at beginning of period | 72640 | 28350 |
| Cash, cash equivalents, and restricted cash at end of period | $47628 | $72640 |
| **Reconciliation of cash, cash equivalents, and restricted cash** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $46772 | $71784 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 856 | 856 |
| **Total cash, cash equivalents, and restricted cash** | $47628 | $72640 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | $636 | $338 |
| **Non-cash investing and financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase |  | 125 |
| &nbsp;&nbsp;&nbsp;Conversion of redeemable convertible preferred stock to common stock |  | 249837 |
| &nbsp;&nbsp;&nbsp;Assumption of Merger warrants liability |  | 51814 |
| &nbsp;&nbsp;&nbsp;Redemption/exercise of Class A common stock warrants |  | 37834 |
| &nbsp;&nbsp;&nbsp;Conversion of Series D preferred stock warrants to Class A common warrants |  | 1160 |
| &nbsp;&nbsp;&nbsp;Right-of-use asset obtained in exchange for lease liability | 1206 |  |
| &nbsp;&nbsp;&nbsp;Vesting of early-exercised stock options, net of cancelations | 197 | 227 |
| &nbsp;&nbsp;&nbsp;Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses |  | 99958 |

---

------

**Non-GAAP Financial Measures**

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes (i) acquisition professional services; and (ii) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, net interest, one-time bonuses and warrant expense in connection with the combination of Hims, Inc. ("Hims") and Oaktree Acquisition Corp. ("OAC"), with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the "Merger"), and amortization of debt issuance costs. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any

------

unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.

**Net Loss to Adjusted EBITDA Reconciliation**

*(In Thousands, Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Revenue | $167203 | $84699 | $526916 | $271878 |
| Net loss | (10907) | (31161) | (65678) | (107659) |
| Stock-based compensation | 12350 | 11952 | 42817 | 67211 |
| Depreciation and amortization | 2010 | 1630 | 7474 | 4075 |
| Acquisition-related costs | 1117 | 891 | 1192 | 8105 |
| Impairment of long-lived assets |  |  | 1127 |  |
| (Benefit) provision for income taxes | (121) | (87) | (31) | (3136) |
| Change in fair value of liabilities | 942 | 9808 | (70) | (3802) |
| Interest (income) / expense, net | (1472) | (92) | (2610) | (390) |
| Merger bonuses |  |  |  | 5219 |
| Warrant expense in connection with Merger |  |  |  | 154 |
| Amortization of debt issuance costs |  |  |  | 144 |
| Adjusted EBITDA | $3919 | $(7059) | $(15779) | $(30079) |
| Net loss as a % of revenue | (7)% | (37)% | (12)% | (40)% |
| Adjusted EBITDA margin | 2% | (8)% | (3)% | (11)% |

---

**Contacts:**

**Investor Relations**

Alice Lopatto

Investors@forhims.com

**Media Relations**

Press@forhims.com

<br>